Dr. Petrylak on Future Research in Prostate Cancer

Daniel P. Petrylak, MD, professor of medicine and urology and co-leader of Cancer Signaling Networks with Yale Cancer Center, as well as a 2017 Giant of Cancer Care^® in Genitourinary Cancers, discusses future research in prostate cancer.

Further refinement of targeted therapies and the molecular tests that determines whether patients are eligible for such therapies is needed, says Petrylak.

For example, patients with ATM mutations tend not to do well with BRCA-targeted therapies such as olaparib (Lynparza) or rucaparib (Rubraca), Petrylak adds.

Additionally, identifying novel combinations that are not tailored toward BRCA mutations may expand the utility of targeted therapy in prostate cancer, Petrylak says.

An investigational concept is to utilize antiangiogenesis agents to induce hypoxia, which could make patients more sensitive to PARP inhibitors, concludes Petrylak.